YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ketamine and Org 25935
Drug: Placebo and Ketamine

First Posted Date: 2008-06-18

Last Posted Date: 2022-03-03

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT00700076

Locations: 🇺🇸
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

Effects of Salvinorin A in Healthy Controls

Early Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Salvinorin A

First Posted Date: 2008-06-18

Last Posted Date: 2022-04-07

Lead Sponsor: Yale University

Target Recruit Count: 105

Registration Number: NCT00700596

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Studies on Aldosterone and Vascular Function

Phase 1

Completed

Conditions: Inflammation

Interventions: Dietary Supplement: low or high sodium diet
Drug: aldosterone
Drug: placebo

First Posted Date: 2008-06-18

Last Posted Date: 2008-06-18

Lead Sponsor: Yale University

Target Recruit Count: 20

Registration Number: NCT00700479

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

Phase 2

Completed

Conditions: Alcohol Drinking

Interventions: Drug: 21mg transdermal nicotine patch (Nicoderm CQ)
Drug: 1mg nicotine nasal spray
Drug: placebo nasal spray

First Posted Date: 2008-06-18

Last Posted Date: 2018-03-12

Lead Sponsor: Yale University

Target Recruit Count: 22

Registration Number: NCT00699556

Locations: 🇺🇸
Connecticut Mental Health Center & Yale-New Haven Hospital, New Haven, Connecticut, United States

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Lenalidomide
Biological: Monocyte derived DCs loaded with KRN7000

First Posted Date: 2008-06-17

Last Posted Date: 2016-06-21

Lead Sponsor: Yale University

Target Recruit Count: 6

Registration Number: NCT00698776

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Ketamine and Nicotine
Drug: Placebo
Drug: Nicotine
Drug: Ketamine

First Posted Date: 2008-06-04

Last Posted Date: 2012-05-09

Lead Sponsor: Yale University

Target Recruit Count: 30

Registration Number: NCT00690170

Locations: 🇺🇸
Veterans Administration Hospital, West Haven, Connecticut, United States

TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes

Phase 3

Completed

Conditions: Type 1 Diabetes

Interventions: Behavioral: TeenCope
Behavioral: Managing Diabetes

First Posted Date: 2008-05-26

Last Posted Date: 2020-04-02

Lead Sponsor: Yale University

Target Recruit Count: 320

Registration Number: NCT00684658

Locations: 🇺🇸
Yale University School of Nursing, New Haven, Connecticut, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 1 locations

Pharmacogenetics of Cannabinoid Response

Early Phase 1

Completed

Conditions: COMT Gene Polymorphism

Interventions: Drug: delta 9 tetrahydrocannabinol

First Posted Date: 2008-05-15

Last Posted Date: 2022-03-09

Lead Sponsor: Yale University

Target Recruit Count: 72

Registration Number: NCT00678730

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

Not Applicable

Withdrawn

Conditions: Drug Dependence

Interventions: Behavioral: Primary Care Counseling
Behavioral: Cognitive-behavioral psychotherapy

First Posted Date: 2008-05-09

Last Posted Date: 2013-07-22

Lead Sponsor: Yale University

Registration Number: NCT00675532

Locations: 🇺🇸
Yale New Haven Hospital Primary Care Center, New Haven, Connecticut, United States

FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer

Phase 2

Completed

Conditions: Gastroesophageal Cancer
Gastric Cancer

Interventions: Drug: FOLFOX
Drug: bevacizumab

First Posted Date: 2008-05-07

Last Posted Date: 2015-02-04

Lead Sponsor: Yale University

Target Recruit Count: 39

Registration Number: NCT00673673

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Medical Oncology & Hematology PC, Hamden, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy